Mark Venghaus
Seminars
Thursday 25th September 2025
Advancing Multiplex Immunofluorescence: Akoya Biosciences is Pioneering Multiplex Immunofluorescence (mIF) Companion Diagnostic Development to Drive Key Clinical Decision Making
11:50 am
- Akoya Biosciences’ multiplex immunofluorescence technology enables high-plex, diagnostic biomarker analysis built upon the PhenoImager HT imaging instrument
- CDx system development requires stringent controls and QC procedures to support multisite deployment capabilities and ensure patient safety
- Akoya Biosciences is a capable diagnostic development partner with multiple late-stage clinical trials and CDx development programs— accelerating spatial diagnostic adoption in precision oncology
